Section Arrow
Quote
EYPT.NASDAQ
- EyePoint Pharmaceuticals
Quotes are at least 15-min delayed:2025/09/05 17:04 EDT
After Hours
Last
 14
-0.01 (-0.07%)
Bid
13.95
Ask
14
High 14.1 
Low 13.77 
Volume 14979 
Regular Hours
Last
 14.01
+2.13 (+17.93%)
Day High 
14.37 
Prev. Close
11.88 
1-M High
12.2399 
Volume 
1.80M 
Bid
13.95
Ask
14
Day Low
11.81 
Open
11.95 
1-M Low
9.4 
Market Cap 
818.86M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 11.77 
20-SMA 11.29 
50-SMA 10.62 
52-W High 13.985 
52-W Low 3.91 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.69/-2.89
Enterprise Value
840.72M
Balance Sheet
Book Value Per Share
3.57
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
43.27M
Operating Revenue Per Share
0.62
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
GNPXGenprex0.2295+0.0738+47.40%0.18PE
After Hours 0.1973 -0.0322 -14.03%
ADAPAdaptimmune Therapeutics plc0.041-0.01-19.61%-- 
After Hours 0.0422 +0.0012 +2.93%
NUVBNuvation Bio3.9+0.48+14.04%-- 
After Hours 3.89 -0.01 -0.26%
KLTOKlotho Neurosciences Inc0.4851-0.0099-2.00%-- 
After Hours 0.479 -0.0061 -1.26%
IOVAIovance Biotherapeutics2.49+0.29+13.18%-- 
After Hours 2.47 -0.02 -0.80%
Quotes are at least 15-min delayed：2025/09/05 17:04 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.